Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.31 (
AMP-activated protein kinase
)
13,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This article emphasizes (1) the utility of routine measurement of pro-insulin to insulin ratio as a specific marker of insulin resistance and predictor of future T2DM, HT and
CAD
, (2) routine C-Peptide estimation to determine which T2DM needs insulin and to monitor the effect of newer drugs which promote beta cell regeneration, (3) routine estimation of adiponectin and TNF alpha and monitor response to thiozolidine drugs which increases adiponectin and decreases TNF alpha production by adipocytes, (4) crucial role of
AMPK
--Cellular energy sensor in mediating the beneficial effects of exercise as well as drugs (adiponectin, metformin) in T2DM, (5) Availability of glucogon suppressors will eliminate the need for giving insulin to T2 DM with normal C Pepetide levels which inevitably causes undesirable weight gain & hypoglycemia.
...
PMID:Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players in type 2 diabetes mellitus. 2064 96
The aim of the present study was to determine whether the endothelial dysfunction associated with CAD (coronary artery disease) and T2D (Type 2 diabetes mellitus) is concomitant with elevated mtROS (mitochondrial reactive oxygen species) production in the endothelium and establish if this, in turn, regulates the activity of endothelial
AMPK
(
AMP-activated protein kinase
). We investigated endothelial function, mtROS production and
AMPK
activation in saphenous veins from patients with advanced
CAD
. Endothelium-dependent vasodilation was impaired in patients with
CAD
and T2D relative to those with
CAD
alone. Levels of mitochondrial H(2)O(2) and activity of
AMPK
were significantly elevated in primary HSVECs (human saphenous vein endothelial cells) from patients with
CAD
and T2D compared with those from patients with
CAD
alone. Incubation with the mitochondria-targeted antioxidant, MitoQ(10) significantly reduced
AMPK
activity in HSVECs from patients with
CAD
and T2D but not in cells from patients with
CAD
alone. Elevated mtROS production in the endothelium of patients with
CAD
and T2D increases
AMPK
activation, supporting a role for the kinase in defence against oxidative stress. Further investigation is required to determine whether pharmacological activators of
AMPK
will prove beneficial in the attenuation of endothelial dysfunction in patients with
CAD
and T2D.
...
PMID:Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes. 2305 46